Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    October 2022
  1. CORTES J, Zhou X, Schmid P
    Pembrolizumab in Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;387:1436.
    PubMed    


  2. ALTUNDAG K
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435-1436.
    PubMed    


  3. SUN R, Wei LJ
    Pembrolizumab in Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:1435.
    PubMed    


    September 2022
  4. MODI S, Gambhire D, Cameron D
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer. Reply.
    N Engl J Med. 2022;387:1145-1146.
    PubMed    


  5. CARROLL HK, Higgins MJ, O'Reilly S
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1144.
    PubMed    


  6. SCHNOG JB, Samson MJ, Duits AJ
    Trastuzumab Deruxtecan in HER2-Low Breast Cancer.
    N Engl J Med. 2022;387:1143-1144.
    PubMed    


    August 2022
  7. CHRISTIAN NT, Borges VF
    What Dobbs Means for Patients with Breast Cancer.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2209249.
    PubMed    


    July 2022
  8. PIVOT X
    Pembrolizumab in the Treatment of Breast Cancer.
    N Engl J Med. 2022;387:273-274.
    PubMed    


  9. CORTES J, Rugo HS, Cescon DW, Im SA, et al
    Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
    N Engl J Med. 2022;387:217-226.
    PubMed     Abstract available


  10. HURVITZ SA
    DESTINY-Changing Results for Advanced Breast Cancer.
    N Engl J Med. 2022;387:75-76.
    PubMed    


    June 2022
  11. JATOI I, Sung H, Jemal A
    The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality.
    N Engl J Med. 2022;386:2349-2352.
    PubMed    


  12. CORTES J, Im SA, Cathcart J
    Trastuzumab Deruxtecan for Breast Cancer. Reply.
    N Engl J Med. 2022;386:2347.
    PubMed    


  13. ZHENG F, Du F, Yuan P
    Trastuzumab Deruxtecan for Breast Cancer.
    N Engl J Med. 2022;386:2346-2347.
    PubMed    


  14. MODI S, Jacot W, Yamashita T, Sohn J, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    N Engl J Med. 2022 Jun 5. doi: 10.1056/NEJMoa2203690.
    PubMed     Abstract available


    May 2022
  15. SCHMID P, Cortes J, Dent R
    Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    N Engl J Med. 2022;386:1771-1772.
    PubMed    


  16. GANGULY S, Gogia A
    Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:1771.
    PubMed    


    March 2022
  17. CORTES J, Kim SB, Chung WP, Im SA, et al
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    N Engl J Med. 2022;386:1143-1154.
    PubMed     Abstract available


  18. HORTOBAGYI GN, Stemmer SM, Burris HA, Yap YS, et al
    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
    N Engl J Med. 2022;386:942-950.
    PubMed     Abstract available


    February 2022
  19. SCHMID P, Cortes J, Dent R, Pusztai L, et al
    Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    N Engl J Med. 2022;386:556-567.
    PubMed     Abstract available


    December 2021
  20. SHARMA V, Kumar A
    Carcinoma en Cuirasse.
    N Engl J Med. 2021;385:2562.
    PubMed    


  21. KALINSKY K, Barlow WE, Gralow JR, Meric-Bernstam F, et al
    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
    N Engl J Med. 2021;385:2336-2347.
    PubMed     Abstract available


    October 2021
  22. TUTT ANJ, Garber JE, Geyer CE Jr
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
    N Engl J Med. 2021;385:1440.
    PubMed    


  23. HOSHI A, Bando H, Sekine I
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439-1440.
    PubMed    


  24. NOZAWA K, Yoshimura A, Iwata H
    Adjuvant Olaparib in BRCA-Mutated Breast Cancer.
    N Engl J Med. 2021;385:1439.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: